A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults (Q40344955)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 27 October 2010

Language	Label	Description	Also known as
English	A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults	scientific article published on 27 October 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

0 references

Orthoebolavirus zairense

0 references

0 references

Julie Ledgerwood

1

object named as

J E Ledgerwood

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

16

object named as

N J Sullivan

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

LaSonji A. Holman

4

object named as

L Holman

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

John R. Mascola

14

object named as

J R Mascola

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Barney S. Graham

19

object named as

B S Graham

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

P Costner

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

N Desai

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

M E Enama

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

G Yamshchikov

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

S Mulangu

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Z Hu

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

C A Andrews

9

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

R A Sheets

10

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

R A Koup

11

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

M Roederer

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

R Bailer

13

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

M G Pau

15

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

J Goudsmit

17

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

G J Nabel

18

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

VRC 205 Study Team

20

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

27 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

304-313

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Crystal structure of the matrix protein VP40 from Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Ebola outbreak has experts rooting for answers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Discovery of swine as a host for the Reston ebolavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Marburg virus infection detected in a common African bat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Fruit bats as reservoirs of Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Isolation of genetically diverse Marburg viruses from Egyptian fruit bats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Exotic emerging viral diseases: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Ebola and Marburg viruses: pathogenesis and development of countermeasures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Development of a preventive vaccine for Ebola virus infection in primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Successful topical respiratory tract immunization of primates against Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Ebola virus-like particles protect from lethal Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Comparison of multiple vaccine vectors in a single heterologous prime-boost trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.10.037

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.10.037

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40344955&oldid=1895780293"